rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Joshua S. Prince

Chief Operating Officer

Company insider

Files Form 4 as: Chief Operating Officer, Vistagen Therapeutics.

In numbers

Trades disclosed
11
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
0
First trade
24 Jun 2024
Last trade
7 Apr 2026
Last filed
9 Apr 2026

Companies traded

Where they are an officer
VTGN Vistagen TherapeuticsOfficer · Biotechnology · last 7 Apr 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
7 Apr 2026filed 9 Apr 2026VTGN Vistagen Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,752 at $0.00filing
7 Apr 2026filed 9 Apr 2026VTGN Vistagen Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—56,248 at $0.00filing
7 Apr 2026filed 9 Apr 2026VTGN Vistagen Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,752 at $0.00filing
7 Apr 2026filed 9 Apr 2026VTGN Vistagen Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—56,248 at $0.00filing
31 Dec 2025filed 5 Jan 2026VTGN Vistagen TherapeuticsBiotechnologySEC FORM 4 Code A$2,4684,386 at $0.5626filing
31 Dec 2025filed 5 Jan 2026VTGN Vistagen TherapeuticsBiotechnologySEC FORM 4 Code A$2,4564,386 at $0.56filing
30 Jun 2025filed 1 Jul 2025VTGN Vistagen TherapeuticsBiotechnologySEC FORM 4 Code A$8,2994,882 at $1.70filing
23 Jun 2025filed 25 Jun 2025VTGN Vistagen Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—100,000 at $0.00filing
31 Dec 2024filed 13 Jan 2025VTGN Vistagen TherapeuticsBiotechnologySEC FORM 4 Code A$8,3083,310 at $2.51filing
28 Jun 2024filed 2 Jul 2024VTGN Vistagen TherapeuticsBiotechnologySEC FORM 4 Code A$7,9062,671 at $2.96filing
24 Jun 2024filed 26 Jun 2024VTGN Vistagen Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—150,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Douglas J. WilliamsonDirector · Director at Vistagen Therapeutics, filing Form 4 there in the last year
Nick B. TresslerChief Financial Officer · Chief Financial Officer at Vistagen Therapeutics, filing Form 4 there in the last year
Shawn SinghPresident and CEO · President and CEO at Vistagen Therapeutics, filing Form 4 there in the last year
Reid G. AdlerChief Legal Officer · Chief Legal Officer at Vistagen Therapeutics, filing Form 4 there in the last year
Angel S. AngelovChief Medical Officer · Chief Medical Officer at Vistagen Therapeutics, filing Form 4 there in the last year